Most times, a Hold rating looks, understandably, neutral. Then there are times that a Hold looks decidedly more negative than that; and Deutsche Bank's reaction to Smith+Nephew (LSE:SN.) feels like the latter.
The German bank, following Tuesday's financial results, has cut its price target to 1,250p from 1,400p (current price 1,099p, down 7% this past week).
Analyst Kane Slutzkin, commenting after attendance at a roundtable with chief financial officer John Rogers, says management gave a notably candid assessment of the competitive pressures facing Smith+Nephew's US Reconstruction business and of prior forecasting errors at the medical devices group.
Deutsche Bank, whilst retaining the Hold, trimmed its 2027-2028 earnings-per-share estimates by a mid-single-digit percentage, primarily reflecting a slower recovery in orthopaedics, and has set its new target using the lower end of management's implied second-half guidance range rather than the top.
Slutzkin said the "burden of proof now rests firmly on execution", adding that while product launches and improving trends in orthopaedics and wound care should support a stronger second half, delivery matters more than messaging, and he flagged sustained execution as the catalyst needed before he would revisit the downside-skewed risk profile.
